R/R HL: cost of treatment in the brentuximab vedotin era

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • A recent study of treatment costs in patients with relapsed/refractory Hodgkin’s lymphoma (R/R HL) who received brentuximab vedotin (BV) illustrates the high and rising economic burden of care in this setting.

Why this matters

  • A 2015 retrospective study of therapy prior t...